Arrowhead director sells $174K in stock

ARROWHEAD PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) director Adeoye Y. Olukotun reported a sale of 2,000 shares of common stock on 2026-08-18 in an open-market or private transaction at $86.96 per share. Following this transaction, he directly holds 31,600 shares, which the company notes include previously reported shares underlying Restricted Stock Units, some of which remain subject to vesting conditions.

Insider Trade Summary

Net Seller: 2,000 shares

Net Sell 1 txn

Insider OLUKOTUN ADEOYE Y

Role Director

Sold 2,000 shs ($174K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	2,000	$86.96	$174K

Holdings After Transaction: Common Stock — 31,600 shares (Direct)

Footnotes (1)

1. F1. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Key Figures

Shares sold: 2,000 shares of Common Stock Sale price per share: $86.96 per share Shares held after transaction: 31,600 shares +1 more

4 metrics

Shares sold 2,000 shares of Common Stock Sale on 2026-08-18 reported by director Adeoye Y. Olukotun

Sale price per share $86.96 per share Price for the 2,000 ARWR shares sold on 2026-08-18

Shares held after transaction 31,600 shares Direct holdings following the reported sale, including RSU-related shares

Net shares sold 2,000 shares Net-sell direction across all transactions in this Form 4

Key Terms

Restricted Stock Units, vesting conditions, open market or private transaction

3 terms

Restricted Stock Units financial

"Includes previously reported shares of common stock underlying Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting conditions financial

"a portion of which are still subject to certain vesting conditions"

Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARWR disclose for Adeoye Y. Olukotun?

Adeoye Y. Olukotun reported a sale of 2,000 ARWR common shares on 2026-08-18 in an open-market or private transaction at $86.96 per share.

How many ARWR shares does Adeoye Y. Olukotun hold after this Form 4 transaction?

After the transaction, Adeoye Y. Olukotun directly holds 31,600 ARWR shares, including shares underlying Restricted Stock Units, some of which are still subject to vesting conditions.

Was the August 18, 2026 ARWR insider trade a purchase or a sale?

The August 18, 2026 transaction reported by Adeoye Y. Olukotun in ARWR was a sale of 2,000 shares of common stock at $86.96 per share.

What role does Adeoye Y. Olukotun have at ARWR in this Form 4?

In this Form 4, Adeoye Y. Olukotun is identified as a director of ARROWHEAD PHARMACEUTICALS, INC. and not as an officer or ten percent owner.

Do Adeoye Y. Olukotun’s ARWR holdings include unvested equity?

Yes. The 31,600 shares reported after the transaction include shares of common stock underlying Restricted Stock Units, and a portion of those RSUs is still subject to vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 05:26 PM Accepted by SEC EDGAR 08/20/2026 - 05:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OLUKOTUN ADEOYE Y

(Last) (First) (Middle)

177 E COLORADO BLVD

STE 700

(Street)

PASADENA CALIFORNIA 91105

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S		2,000	D	$86.96	31,600(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.

Remarks:

	/s/Adeoye Olukotun	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)